Eterna Therapeutics Inc. announced the appointment of James Bristol, Ph.D., to its Board of Directors. Dr. Bristol is a seasoned biopharmaceutical executive who has excelled as a corporate partner, board member, and strategic and technical advisor within industry, said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna. Dr. Bristol added, Eternas mRNA cell engineering platform is a stand out in the industry and I look forward to working with the leadership team and Board to fully realize its potential.

Dr. Bristols career in research &development and drug discovery has spanned more than 30 years. Since his retirement from Pfizer in 2007, he has spent the subsequent 16 years as a consultant, actively engaged in various Boards of Directors, Scientific Advisory Board and advisory roles in the biopharmaceutical industry, including Chairman of the Board of Directors of Deciphera Pharmaceuticals, Lead Independent Director of Erasca, and Senior Advisor to Frazier Life Sciences. Prior to his retirement, Dr. Bristol was Senior Vice President, Worldwide Drug Discovery Research at Pfizer, overseeing discovery collaborations and managing a large team of scientists across multiple company sites in the U.S., U.K., and Japan who produced an industry-leading number of drug development candidates across 11 broadly defined therapeutic areas.

Before that, he worked at Parke-Davis for 20 years, where he held positions of increasing responsibility in Chemistry and Drug Discovery and participated in collaboration oversight committees. Early in his career, Dr. Bristol was a Principal Scientist at Schering-Plough. His drug discovery research has resulted in numerous publications, abstracts, and patents.

Dr. Bristol holds a Ph.D. in Organic Chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.